Search

Your search keyword '"Alexander Pasternak"' showing total 64 results

Search Constraints

Start Over You searched for: Author "Alexander Pasternak" Remove constraint Author: "Alexander Pasternak"
64 results on '"Alexander Pasternak"'

Search Results

1. Highlights from the 22nd International AIDS Conference (AIDS 2018), 22–27 July 2018, Amsterdam, the Netherlands

2. Pharmacological inhibition of hematopoietic progenitor kinase 1 positively regulates T-cell function.

5. Immune and viral correlates of 'secondary viral control' after treatment interruption in chronically HIV-1 infected patients.

6. Rapid Evolution of a Fragment-like Molecule to Pan-Metallo-Beta-Lactamase Inhibitors: Initial Leads toward Clinical Candidates

7. 1723. MK-3866, a metallo-β-lactamase inhibitor, is not subject to efflux in Pseudomonas aeruginosa

8. Discovery of Diaminopyrimidine Carboxamide HPK1 Inhibitors as Preclinical Immunotherapy Tool Compounds

9. Discovery of Potent and Orally Available Bicyclo[1.1.1]pentane-Derived Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors

10. Oxetane Promise Delivered: Discovery of Long-Acting IDO1 Inhibitors Suitable for Q3W Oral or Parenteral Dosing

11. Discovery of MK-8153, a Potent and Selective ROMK Inhibitor and Novel Diuretic/Natriuretic

12. Carbamate and N-Pyrimidine Mitigate Amide Hydrolysis: Structure-Based Drug Design of Tetrahydroquinoline IDO1 Inhibitors

13. The therapeutic potential of targeting the Kir1.1 (renal outer medullary K+) channel

14. Improvement of hERG-ROMK index of spirocyclic ROMK inhibitors through scaffold optimization and incorporation of novel pharmacophores

15. The design and synthesis of novel spirocyclic heterocyclic sulfone ROMK inhibitors as diuretics

16. Pharmacological inhibition of hematopoietic progenitor kinase 1 positively regulates T-cell function

17. Discovery of a potent and selective ROMK inhibitor with improved pharmacokinetic properties based on an octahydropyrazino[2,1-c][1,4]oxazine scaffold

18. Discovery of MK-7145, an Oral Small Molecule ROMK Inhibitor for the Treatment of Hypertension and Heart Failure

19. Abstract 427: Inhibition of Myocardial Romk Channels Blocks Ischemic Preconditioning Induced Cardio-protection

20. Discovery of a Potent and Selective ROMK Inhibitor with Pharmacokinetic Properties Suitable for Preclinical Evaluation

21. Abstract 068: Impact of Renal Outer Medullary Potassium Channel Inhibition on Afferent Arteriolar Tone in Rats With Type 1 Diabetes

22. Discovery of a novel sub-class of ROMK channel inhibitors typified by 5-(2-(4-(2-(4-(1H-Tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)ethyl)isobenzofuran-1(3H)-one

23. Inhibition of ROMK blocks macula densa tubuloglomerular feedback yet causes renal vasoconstriction in anesthetized rats

24. Chronic Inhibition of Renal Outer Medullary Potassium Channel Not Only Prevented but Also Reversed Development of Hypertension and End-Organ Damage in Dahl Salt-Sensitive Rats

25. The Renal Outer Medullary Potassium Channel Inhibitor, MK-7145, Lowers Blood Pressure, and Manifests Features of Bartter's Syndrome Type II Phenotype

26. The Inwardly Rectifying Potassium Channel Kir1.1: Development of Functional Assays to Identify and Characterize Channel Inhibitors

27. CCR2 Antagonists

28. Design, synthesis, and structure–activity relationship of novel CCR2 antagonists

29. Potent heteroarylpiperidine and carboxyphenylpiperidine 1-alkyl-cyclopentane carboxamide CCR2 antagonists

30. SAR exploration at the C-3 position of tetrahydro-β-carboline sstr3 antagonists

31. Differentiation of ROMK potency from hERG potency in the phenacetyl piperazine series through heterocycle incorporation

32. 4-Amino-2-alkyl-butyramides as small molecule CCR2 antagonists with favorable pharmacokinetic properties

33. The μ-opioid receptor subtype is required for the anorectic effect of an opioid receptor antagonist

34. Novel, Orally Bioavailable γ-Aminoamide CC Chemokine Receptor 2 (CCR2) Antagonists

36. Design, Synthesis, and Biological Evaluation of Monopyrrolinone-Based HIV-1 Protease Inhibitors

37. Discovery of MK-1421, a Potent, Selective sstr3 Antagonist, as a Development Candidate for Type 2 Diabetes

38. Potent, orally bioavailable somatostatin agonists: Good absorption achieved by urea backbone cyclization

39. Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2

40. [Untitled]

41. Pharmacologic inhibition of the renal outer medullary potassium channel causes diuresis and natriuresis in the absence of kaliuresis

43. Viscosity evaluation of the mixture of coal tars from collection main and primary cooler on the base of rheometer measurements and empirical formulas

44. Discovery of Selective Small Molecule ROMK Inhibitors as Potential New Mechanism Diuretics

45. Enantioretentive alkylation of oxazolidinone aluminum enolates with epoxides: Preparation of uncoded homoserine analogs

46. Stimulation of Glucose-Dependent Insulin Secretion by a Potent, Selective sst3 Antagonist

48. ChemInform Abstract: Pyrrolinone-Based HIV Protease Inhibitors. Design, Synthesis, and Antiviral Activity: Evidence for Improved Transport

50. Discovery of a Potent and Orally Bioavailable CCR2 and CCR5 Dual Antagonist

Catalog

Books, media, physical & digital resources